เข้าสู่ระบบ สมัครสมาชิก
มากกว่า

muscarinic antagonists การใช้

ประโยคมือถือ
  • Methscopolamine, a methylated derivative of muscarinic antagonist structurally similar to the neurotransmitter acetylcholine.
  • In the case of muscarinic antagonists, they can also bind to histamine receptors.
  • Trospium chloride is a muscarinic antagonist.
  • "' Methoctramine "'is a polymethylene tetraamine that acts as a muscarinic antagonist.
  • Pralidoxime is often used with atropine ( a muscarinic antagonist ) to help reduce the parasympathetic effects of organophosphate poisoning.
  • Important muscarinic antagonists include atropine, Hyoscyamine, hyoscine butylbromide and hydrobromide, ipratropium, tropicamide, cyclopentolate, and pirenzepine.
  • Muscarinic antagonists, or chemicals that block ACh, impair spatial learning when administered prior to a training task among rats.
  • At first it showed activity as a slight muscarinic antagonist, but with recent studies it has showed other interesting neurological activities.
  • The development of a muscarinic antagonist based on himbacine failed but an analog, vorapaxar, has been approved by the FDA as a thrombin receptor antagonist.
  • Muscarinic antagonists such as ipratropium bromide can also be effective in treating asthma, since acetylcholine is known to cause smooth muscle contraction, especially in the bronchi.
  • "' Cyclopentolate "'is a medication commonly used during pediatric eye examinations that dilates the eye ( mydriatic ), prevents muscarinic receptors ( muscarinic antagonist ).
  • Pharmacological studies using the centrally acting muscarinic antagonist scopolamine inhibited lamb recognition, which may be due to a blockade of muscarinic receptors in projection areas of basal forebrain cholinergic neurons.
  • "' Umeclidinium bromide "'( trade name "'Incruse Ellipta "', GSK ) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease ( COPD ).
  • "' Aclidinium bromide "'( INN ) is a long-acting, inhaled muscarinic antagonist ( LAMA ) approved in the US on July 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease ( COPD ).